Metoprololo Hexal

Metoprolol Tartrate, the active ingredient in Metoprololo Hexal, is a beta blocker presented as a tablet for oral use. It treats hypertension, angina, post‑myocardial infarction care, chronic heart failure and certain cardiac arrhythmias in adult patients. It is indicated for adult patients with elevated blood pressure, stable angina, after myocardial infarction, and for long‑term management of heart failure, helping to improve survival and reduce cardiovascular events.

GNH USA supplies Metoprololo Hexal as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide. The company follows Good Distribution Practice (GDP) standards, ensures product integrity through controlled shipping, and provides regulatory documentation to support import requirements across EU, Asia, Africa and the Americas.

Metoprolol Tartrate is a beta‑adrenergic blocker used in cardiovascular disease management.

Hypertension: lowers blood pressure by reducing cardiac output and inhibiting renin release. Angina pectoris: relieves chest pain by decreasing myocardial oxygen demand through heart‑rate and contractility reduction. Post‑myocardial infarction: improves survival and lowers risk of recurrent infarction by stabilising cardiac rhythm and limiting remodelling. Chronic heart failure: enhances left‑ventricular function and reduces hospitalisation by controlling heart rate and neuro‑hormonal activation. Cardiac arrhythmias: controls ventricular rate in atrial fibrillation and other supraventricular tachyarrhythmias.

Metoprolol Tartrate may cause a range of adverse reactions, varying from mild to serious.

Common Side Effects: - Fatigue - Dizziness or light‑headedness - Bradycardia (slow heart rate) - Cold extremities - Gastrointestinal discomfort (nausea, abdominal pain) - Headache

Serious or Rare Side Effects: - Severe bradycardia or heart block - Marked hypotension - Bronchospasm, especially in patients with asthma - Acute heart‑failure exacerbation - Allergic reactions (rash, angioedema, anaphylaxis) - Depression or mood changes

Before prescribing Metoprolol Tartrate, clinicians should consider several safety precautions.

Assess cardiovascular status: evaluate baseline heart rate and blood pressure to avoid excessive bradycardia or hypotension. Review respiratory history: use cautiously in patients with asthma or chronic obstructive pulmonary disease due to possible bronchospasm. Monitor glucose control: beta‑blockade may mask hypoglycaemia symptoms in diabetic patients. Avoid abrupt discontinuation: sudden cessation can precipitate rebound hypertension, tachycardia, or angina. Consider renal/hepatic function: dose adjustments may be needed in severe impairment. Store at ambient temperature: keep below 25°C in the original packaging, protect from moisture and direct sunlight.

Metoprolol Tartrate can interact with other medicines, altering its efficacy or safety profile.

Major Interactions (Avoid): - Other β‑blockers or calcium‑channel blockers (verapamil, diltiazem) → additive bradycardia or AV block. - Anti‑arrhythmic agents (e.g., amiodarone, quinidine) → increased risk of conduction disturbances. - Clonidine withdrawal → severe rebound hypertension. - Insulin or oral hypoglycemics → mask hypoglycaemia signs. - Non‑selective β‑blockers → excessive β‑blockade.

Moderate Interactions (Monitor Closely): - NSAIDs (ibuprofen, naproxen) → may reduce antihypertensive effect. - Diuretics (thiazides, loop diuretics) → enhance hypotensive response. - Antidepressants (SSRIs, tricyclics) → potential for additive cardiac effects. - Antipsychotics (haloperidol, risperidone) → may increase QT prolongation risk. - CYP2D6 inhibitors (fluoxetine, paroxetine) → raise metoprolol plasma levels.